NBIX : Summary for Neurocrine Biosciences, Inc. - Yahoo Finance

U.S. Markets close in 3 hrs 2 mins

Neurocrine Biosciences, Inc. (NBIX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
41.87-0.48 (-1.13%)
As of 12:57PM EDT. Market open.
People also watch
ALKSPGNXLGNDNKTRMDCO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close42.35
Open42.26
Bid41.65 x 300
Ask41.71 x 200
Day's Range41.61 - 42.50
52 Week Range34.68 - 55.15
Volume204,203
Avg. Volume1,036,129
Market Cap3.65B
Beta1.75
PE Ratio (TTM)-25.69
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Benzinga4 days ago

    Setting The Stage For Neurocrine's Pending PDUFA Date, Barclays Remains Positive

    Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) is on the verge of becoming a commercial biotech company, as its PDUFA date for Ingrezza in tardive dyskynesia (TD) approaches. The FDA is expected to announce ...

  • PR Newswire7 days ago

    Neurocrine Announces American Journal of Psychiatry Publication of Positive Results from Kinect 3 Phase III Study of INGREZZA TM (valbenazine) for the Treatment of Tardive Dyskinesia

    SAN DIEGO, March 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX), a biotechnology company focused on neurologic, psychiatric and endocrine related disorders, announced today that positive results from the Kinect 3 Phase III study of INGREZZA (valbenazine) for the treatment of tardive dyskinesia (TD) were published online by the American Journal of Psychiatry (DOI: 10.1176/appi.ajp.2017.16091037). Once-daily INGREZZA, a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, demonstrated a significant and meaningful reduction in TD symptoms compared with placebo in participants with underlying schizophrenia, schizoaffective disorder or mood disorder. Tardive dyskinesia is thought to affect at least 500,000 people in the U.S. and is characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face.  These symptoms are associated with chronic exposure to dopamine receptor blockers such as antipsychotic medications and can be severe, persistent and irreversible.

  • Neurocrine Biosciences, Inc. :NBIX-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017
    Capital Cubelast month

    Neurocrine Biosciences, Inc. :NBIX-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017

    Categories: Yahoo Finance Get free summary analysis Neurocrine Biosciences, Inc. reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of Neurocrine Biosciences, Inc. – Palatin Technologies, Inc., Pfizer Inc., Eli Lilly and Company and AbbVie, Inc. (PTN-US, PFE-US, LLY-US and ABBV-US) that have also reported for this period. ... Read more (Read more...)